ProPhase Labs, Inc. Operating Lease, Expense
ProPhase Labs, Inc. (PRPH) reported Operating Lease, Expense of $422.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-19
- ProPhase Labs, Inc. operating lease, expense for the quarter ending 2025-12-31 was $165.00K, a 65.48% decline year-over-year.
- ProPhase Labs, Inc. operating lease, expense for the quarter ending 2025-09-30 was $18.00K, a 92.47% decline year-over-year.
- ProPhase Labs, Inc. operating lease, expense for the quarter ending 2025-06-30 was $165.00K, a 30.96% decline year-over-year.
- ProPhase Labs, Inc. operating lease, expense for the quarter ending 2025-03-31 was $239.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. operating lease, expense for fiscal 2025 was $422.00K, a 55.86% decline from fiscal 2024.
- ProPhase Labs, Inc. operating lease, expense for fiscal 2024 was $956.00K.
- ProPhase Labs, Inc. operating lease, expense for fiscal 2022 was $816.00K, a 0.00% change from fiscal 2021.
- ProPhase Labs, Inc. operating lease, expense for fiscal 2021 was $816.00K, a 6700.00% increase from fiscal 2020.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $183.00K derived: sum of 2 quarters · filed 2026-06-01 | $348.00K derived: sum of 3 quarters · filed 2026-08-19 | $422.00K 10-K · filed 2026-06-01 | ||
| 2025-09-30 | $18.00K 10-Q · filed 2025-11-19 | $183.00K derived: sum of 2 quarters · filed 2026-08-19 | $257.00K 10-Q · filed 2025-11-19 | $900.00K derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-06-30 | $165.00K 10-Q · filed 2026-08-19 | $404.00K 10-Q · filed 2026-08-19 | $882.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.12M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-03-31 | $239.00K 10-Q/A · filed 2026-07-09 | $717.00K derived: sum of 2 quarters · filed 2026-07-09 | $956.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.20M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2024-12-31 | $478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $717.00K derived: sum of 2 quarters · filed 2026-06-01 | $956.00K derived: sum of 3 quarters · filed 2026-06-01 | $956.00K 10-K · filed 2026-06-01 | ||
| 2024-09-30 | $239.00K 10-Q · filed 2025-11-19 | $478.00K derived: sum of 2 quarters · filed 2025-11-19 | $478.00K 10-Q · filed 2025-11-19 | $717.00K 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $239.00K 10-Q · filed 2025-08-13 | $478.00K 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $239.00K 10-Q · filed 2025-05-20 | |||||
| 2023-09-30 | $239.00K 10-Q · filed 2024-11-13 | $215.00K 10-Q · filed 2023-11-13 | $537.00K derived: sum of 2 quarters · filed 2024-11-13 | $717.00K 10-Q · filed 2024-11-13 | $945.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $298.00K 10-Q · filed 2024-08-14 | $502.00K 10-Q · filed 2024-08-14 | $706.00K derived: sum of 3 quarters · filed 2024-08-14 | $910.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $204.00K 10-Q · filed 2024-05-10 | $408.00K derived: sum of 2 quarters · filed 2024-05-10 | $612.00K derived: sum of 3 quarters · filed 2024-05-10 | $816.00K derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $408.00K derived: sum of 2 quarters · filed 2023-11-13 | $612.00K derived: sum of 3 quarters · filed 2023-11-13 | $816.00K 10-K · filed 2023-03-29 | ||
| 2022-09-30 | $204.00K 10-Q · filed 2023-11-13 | $408.00K derived: sum of 2 quarters · filed 2023-11-13 | $612.00K 10-Q · filed 2023-11-13 | $817.00K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $204.00K 10-Q · filed 2023-08-11 | $408.00K 10-Q · filed 2023-08-11 | $613.00K derived: sum of 3 quarters · filed 2023-08-11 | $817.00K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $204.00K 10-Q · filed 2023-05-12 | $409.00K derived: sum of 2 quarters · filed 2023-05-12 | $613.00K derived: sum of 3 quarters · filed 2023-05-12 | $817.00K derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $409.00K derived: sum of 2 quarters · filed 2023-03-29 | $613.00K derived: sum of 3 quarters · filed 2023-03-29 | $816.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $204.00K 10-Q · filed 2022-11-10 | $408.00K derived: sum of 2 quarters · filed 2022-11-10 | $611.00K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $204.00K 10-Q · filed 2022-08-12 | $408.00K 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | $204.00K 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | $12.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |